A5089773196- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Genomic variations and chromosomal abnormalities
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- HIV/AIDS drug development and treatment
- Drug-Induced Adverse Reactions
- Chronic Lymphocytic Leukemia Research
- Intracranial Aneurysms: Treatment and Complications
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- DNA Repair Mechanisms
- Cardiovascular and Diving-Related Complications
- Microtubule and mitosis dynamics
- Cellular Mechanics and Interactions
- Machine Learning in Bioinformatics
Chinese University of Hong Kong
2008-2025
University of Hong Kong
2014-2024
Queen Mary Hospital
2021
Memorial Sloan Kettering Cancer Center
2018
The University of Texas MD Anderson Cancer Center
2018
Workers Compensation Board of Alberta
2018
Allegheny General Hospital
2018
Allegheny Health Network
2018
Jackson Laboratory
2018
Agilent Technologies (United States)
2018
An in vitro drug screening using primary AML samples identified homoharringtonine (omacetaxine mepesuccinate) as an effective adjunct for treatment of FLT3-ITD AML.
Abstract The present study aimed to define a subtype of complex/monosomal karyotype (CK/MK) acute myeloid leukemia (AML) by its distinct clinical features, p53 signaling and responses targeting agents. Ninety‐eight young adults (range: 21‐60 years; median: 49 years) with CK/MK AML were studied. They received standard induction, consolidation allogeneic hematopoietic stem cell transplantation from siblings or matched unrelated donors if available. Chromosomal abnormalities most commonly...
Background Omacetaxine mepesuccinate (OME) has antileukemic effects against acute myeloid leukemia (AML) carrying an internal tandem duplication of Fms‐like tyrosine kinase 3 ( FLT3 ‐ITD). A phase 2 clinical trial was conducted to evaluate a combination treatment sorafenib and omacetaxine (SOME). Methods Relapsed or refractory (R/R) newly diagnosed patients were treated with (200‐400 mg twice daily) OME (2 for 7 (first course) 5 days (second course onward) every 21 until disease progression...
Abstract Purpose: Myelodysplastic syndrome and acute myeloid leukemia with complex monosomy karyotypes show a high prevalence of TP53 mutations (TP53m), poor response to induction chemotherapy, adverse outcomes. These diseases may respond decitabine, but the mechanisms are presently unclear. Experimental Design: Patients myelodysplastic were treated decitabine for 10 days in phase II clinical study. In this study, we collected serial samples from patients before at completion treatment,...
Lung cancer accounts for over a quarter of deaths, with non-small cell lung (NSCLC) accounting approximately 80% cases. Several genome studies have been undertaken in both models NSCLC and clinical samples to identify alterations underlying disease behaviour, many identified recurring aberrations chromosome 7. The presence 7 that do not span the well-studied oncogenes EGFR (at 7p11.2) MET 7q31.2) has raised hypothesis additional genes on this contribute tumourigenesis. In study, we...
Article5 March 2020Open Access Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia Bai-Liang He Division of Hematology, Department Medicine, Li Ka Shing Faculty The University Hong Kong, Kong SAR, China Guangdong Provincial Key Laboratory Biomedical Imaging, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Province, Search for more papers by this author Ning Yang Cheuk Him Man Nelson Ka-Lam Ng Chae-Yin Cher Ho-Ching Leung Leo Lai-Hok Kan Bowie...
Cell-to-cell interactions are complex processes that involve physical interactions, chemical binding, and biological signaling pathways. Identification of the functions special pathway in cell-to-cell interaction from very first contact will help characterize mechanism underlying advance new drug discovery. This paper reported a case study characterizing initial between leukemia cancer cells bone marrow stromal cells, through use an optical tweezers-based cell manipulation tool. Optical...
Summary Trisomy karyotype occurs in 5%–10% of AML. Its mutational landscape and prognostic significance are not well defined. A cohort 156 trisomy AML patients was analysed, with reference to 615 cytogenetically normal (CN) patients. showed distinct more prevalent SMC1A , N/KRAS ASXL1 BCOR but fewer CEBPA bZIP NPM1 mutations ≤60, those >60. NRAS were associated poor outcome AML, whereas DNMT3A FLT3‐ITD had neutral effect. appeared biologically from CN‐AML.
Abstract Gain-of-function kinase mutations are common in AML and usually portend an inferior prognosis. We reported a novel mechanism whereby mutants induced intracellular alkalization characteristic oncogenesis. Thirteen kinases were found to activate sodium/hydrogen exchanger (NHE1) normal hematopoietic progenitors, of which FLT3-ITD, KRAS G12D , BTK phosphorylated NHE1 maintained alkaline pH (pHi) supported survival cells. Primary samples with also showed increased phosphorylation...